GlassScriptPhysician profile
Paul G Pascarella
NPI 1336109958
$8,107.97
in general payments reported to CMS, 2019-2025
24 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,662 · 2020: $339 · 2021: $540 · 2022: $1,349 · 2023: $1,211 · 2024: $785 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,218.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,897.11 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $1,583.13 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Coopervision INC. | $1,243.77 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Paragon Crt |
| Bausch & Lomb Americas INC. | $620.47 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $486.69 | 2019-2021 | |
| Visioneering Technologies, INC. | $317.27 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $279.55 | 2021-2025 | Cequa |
| Lumenis Be INC | $252.05 | 2023 | Optilight |
| Rxsight INC | $234.66 | 2024 | Light Adjustable Lens (Lal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Lkc Technologies, INC. | $210.75 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $148.63 | 2019-2022 | |
| Oyster Point Pharma, INC. | $147.72 | 2022-2024 | Tyrvaya |
| Tarsus Pharmaceuticals, INC. | $141.07 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $101.20 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $83.32 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $70.19 | 2019 | |
| Glaukos Corporation | $61.52 | 2022 | |
| Abbvie INC. | $49.47 | 2022 | |
| Harrow Eye, LLC | $45.02 | 2025 | Vevye |
| Abb Con-Cise Optical Group LLC | $38.13 | 2019-2023 | Contact Lens, Spectacle Lenses |
| Allergan, INC. | $33.66 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $27.83 | 2022 | |
| Astellas Pharma US INC | $18.95 | 2025 | Izervay |
| Optos, INC. | $15.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Pascarella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.